EHA 2018 | Population-based studies for ibrutinib in CLL
Since its approval in late 2014, ibrutinib has primarily been studied in clinical trials, such as RESONATE (NCT01578707), and in compassionate use programs. In this video, Lina van der Straten, PhD, of the Albert Schweitzer Hospital, Dordrecht, Netherlands, outlines a recent study that aims to determine the effect of ibrutinib on patients with chronic lymphocytic leukemia (CLL) within a population-based setting. Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Dr van der Straten explains the key preliminary results from her initial study on a group of patients treated with ibrutinib between 2014-15, with follow-ups in October 2016. Dr van der Straten also compares these results to those obtained in both the RESONATE study and in compassionate use programs.
Get great new content delivered to your inboxSign up